Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
An oncolytic adenovirus shows antitumor efficacy in patient-derived models of intraocular retinoblastoma and appears safe for human use.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Despite these advances, adenovirus vectors are typically not used for retinal gene therapy and targeting retinoblastoma with oncolytic adenovirus VCN-01is the only Ad vectored clinical trial in the ocular field.62,63”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [63]
Citations
Cites
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
Mutation and cancer: statistical study of retinoblastoma
Knudson, A. G. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.4.820 · Cited by 7,612
Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.72351 · Cited by 6,277
Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachment
Wickham, T. J., Mathias, P., Cheresh, D. A., & Nemerow, G. R. (1993) · Cell · doi:10.1016/0092-8674(93)90231-e · Cited by 2,199
Oncolytic viruses: a new class of immunotherapy drugs
Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4663 · Cited by 1,642 · cited 1×
“Because adenoviruses activate induction of systemic antitumor immunity (53), we speculate that immune activation upon oncolysis might be beneficial for patients with solid bulky tumors in the retina.”
BackgroundSibling rivalry in the E2F family
Trimarchi, J. M., & Lees, J. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm714 · Cited by 1,158 · cited 1×
“E2Fs are a broad family of transcription factors with conserved DNA binding domains that bind target promoters controlling the expression of key cell cycle regulators (16, 17).”
BackgroundEmerging roles of E2Fs in cancer: an exit from cell cycle control
Chen, H.-Z., Tsai, S.-Y., & Leone, G. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2696 · Cited by 1,021
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
Fueyo, J., Gomez-Manzano, C., Alemany, R., Lee, P. S., McDonnell, T. J., Mitlianga, P., Shi, Y.-X., Levin, V. A., Yung, W. K. A., & Kyritsis, A. P. (2000) · Oncogene · doi:10.1038/sj.onc.1203251 · Cited by 764 · cited 11×
“RB1−/− cells lacked expression of RB1 protein and showed twofold higher E2F-1 expression than RB1+/− cells (fig.”
BackgroundInfluentialSelf-citationPharmacokinetic aspects of retinal drug delivery
del Amo, E. M., Rimpelä, A.-K., Heikkinen, E., Kari, O. K., Ramsay, E., Lajunen, T., Schmitt, M., Pelkonen, L., Bhattacharya, M., Richardson, D., et al. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.12.001 · Cited by 693
Intraocular Retinoblastoma: the Case for a New Group Classification
LINNMURPHREE, A. (2005) · Ophthalmology Clinics of North America · doi:10.1016/j.ohc.2004.11.003 · Cited by 683 · cited 1×
“No correlation between the immunohistochemistry (IHC) score and clinical data of the enucleated eyes [sex, laterality, age, tumor differentiation, International Classification of Retinoblastoma (ICRB) group (30), or treatment] was observed (tables S3 and S4).”
BackgroundImmune responses to gene therapy vectors: influence on vector function and effector mechanisms
Bessis, N., GarciaCozar, F. J., & Boissier, M.-C. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302364 · Cited by 633
A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F
Helin, K., Lees, J. A., Vidal, M., Dyson, N., Harlow, E., & Fattaey, A. (1992) · Cell · doi:10.1016/0092-8674(92)90107-n · Cited by 613
Molecular mechanisms underlying RB protein function
Dick, F. A., & Rubin, S. M. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3567 · Cited by 569 · cited 1×
“Upon receiving a mitogenic signal, RB1 is phosphorylated by cyclin-dependent kinases, causing inability to bind E2F and promoting cell cycle progression from G1 to S (18).”
BackgroundDimaras, H., Corson, T. W., Cobrinik, D., White, A., Zhao, J., Munier, F. L., Abramson, D. H., Shields, C. L., Chantada, G. L., Njuguna, F., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.21 · Cited by 553 · cited 1×
“New knowledge about the biology and genetics of retinoblastoma has provided therapeutic leads (7, 8).”
BackgroundSelf-citationA novel retinoblastoma therapy from genomic and epigenetic analyses
Zhang, J., Benavente, C. A., McEvoy, J., Flores-Otero, J., Ding, L., Chen, X., Ulyanov, A., Wu, G., Wilson, M., Wang, J., et al. (2012) · Nature · doi:10.1038/nature10733 · Cited by 516
Generation of Induced Pluripotent Stem Cells from Human Cord Blood Using OCT4 and SOX2
Giorgetti, A., Montserrat, N., Aasen, T., Gonzalez, F., Rodríguez-Pizà, I., Vassena, R., Raya, A., Boué, S., Barrero, M. J., Corbella, B. A., et al. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.09.008 · Cited by 408
Munier, F. L., Gaillard, M.-C., Balmer, A., Soliman, S., Podilsky, G., Moulin, A. P., & Beck-Popovic, M. (2012) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2011-301450 · Cited by 384
Self-citationGenetic Origin of Mutations Predisposing to Retinoblastoma
Cavenee, W. K., Hansen, M. F., Nordenskjold, M., Kock, E., Maumenee, I., Squire, J. A., Phillips, R. A., & Gallie, B. L. (1985) · Science · doi:10.1126/science.3983638 · Cited by 359
Fueyo, J., Alemany, R., Gomez-Manzano, C., Fuller, G. N., Khan, A., Conrad, C. A., Liu, T.-J., Jiang, H., Lemoine, M. G., Suzuki, K., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.9.652 · Cited by 350 · cited 1×
“Compared to astrocytes, a cell type reported to express adenovirus receptors (29), retinoblastoma cultures showed similar expression of CXADR (fig.”
BackgroundSelf-citationTao, N., Gao, G.-P., Parr, M., Johnston, J., Baradet, T., Wilson, J. M., Barsoum, J., & Fawell, S. E. (2001) · Molecular Therapy · doi:10.1006/mthe.2000.0227 · Cited by 321
CRISPR/Cas9-based engineering of the epigenome
Pulecio, J., Verma, N., Mejía-Ramírez, E., Huangfu, D., & Raya, A. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2017.09.006 · Cited by 300
Treatment of Retinoblastoma in 2015: Agreement and Disagreement
Abramson, D. H., Shields, C. L., Munier, F. L., & Chantada, G. L. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2015.3108 · Cited by 238
Self-citationRb suppresses human cone-precursor-derived retinoblastoma tumours
Xu, X. L., Singh, H. P., Wang, L., Qi, D.-L., Poulos, B. K., Abramson, D. H., Jhanwar, S. C., & Cobrinik, D. (2014) · Nature · doi:10.1038/nature13813 · Cited by 235
RB1 gene mutations in retinoblastoma
Lohmann, D. R. (1999) · Human Mutation · doi:10.1002/(sici)1098-1004(199910)14:4<283::aid-humu2>3.0.co;2-j · Cited by 214
Cell Receptors Involved in Adenovirus Entry
Nemerow, G. R. (2000) · Virology · doi:10.1006/viro.2000.0468 · Cited by 194
Rb regulates proliferation and rod photoreceptor development in the mouse retina
Zhang, J., Gray, J., Wu, L., Leone, G., Rowan, S., Cepko, C. L., Zhu, X., Craft, C. M., & Dyer, M. A. (2004) · Nature Genetics · doi:10.1038/ng1318 · Cited by 190 · cited 1×
“In both cases, retinal cells reveal dysfunctional status of the retinoblastoma protein (RB1), which promotes uncontrolled cell division and initiates retinoblastoma oncogenesis (13, 14).”
BackgroundStrategies to manage retinoblastoma in developing countries
Chantada, G. L., Qaddoumi, I., Canturk, S., Khetan, V., Ma, Z., Kimani, K., Yeniad, B., Sultan, I., Sitorus, R. S., Tacyildiz, N., et al. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.22843 · Cited by 167 · cited 1×
“INTRODUCTION Each year, it is estimated that 8000 cases of retinoblastoma—a tumor of the developing retina—are diagnosed worldwide, representing 11% of cancers in children less than 1 year of age (1).”
BackgroundSelf-citationLoudianos, G., Dessi, V., Lovicu, M., Angius, A., Figus, A., Lilliu, F., De Virgiliis, S., Nurchi, A. M., Deplano, A., Moi, P., et al. (1999) · Human Mutation · doi:10.1002/(sici)1098-1004(199910)14:4<294::aid-humu4>3.0.co;2-9 · Cited by 166
Chévez-Barrios, P., Chintagumpala, M., Mieler, W., Paysse, E., Boniuk, M., Kozinetz, C., Hurwitz, M. Y., & Hurwitz, R. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.1883 · Cited by 143 · cited 1×
“A previous clinical study of an intravitreous adenovirus vector for gene therapy in pediatric patients with retinoblastoma did not detect adenovirus genomes in the blood of eight patients receiving up to 1011 vp per injection (49).”
MethodEfficacy and Toxicity of Intravitreous Chemotherapy for Retinoblastoma: Four-Year Experience
Francis, J. H., Brodie, S. E., Marr, B. P., Zabor, E. C., Mondesire-Crump, I., & Abramson, D. H. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2016.12.015 · Cited by 137 · cited 1×
“Otherwise, intensive local chemotherapy might preserve eyes; however, there may be an associated cost of compromised vision due to long-term retinal toxicity (5, 6).”
BackgroundRB1 gene inactivation by chromothripsis in human retinoblastoma
McEvoy, J. D., Nagahawatte, P., Finkelstein, D., Richards‐Yutz, J., Valentine, M. B., Ma, J., Mullighan, C. G., Song, G., Chen, X. '., Wilson, M. W., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1686 · Cited by 130
Rodríguez-García, A., Giménez-Alejandre, M., Rojas, J. J., Moreno, R., Bazan-Peregrino, M., Cascalló, M., & Alemany, R. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2213 · Cited by 120 · cited 5×
“To enhance interaction with integrins 5 (gene ITGA5) and v (gene ITGAV), the fiber heparan sulfate-glycosaminoglycans (HSG)–binding domain Lys-LysThr-Lys (KKTK) was replaced with an Arg-Gly-Asp-Lys (RGDK) domain in VCN-01 (21).”
BackgroundMethodInfluentialSelf-citationMetastatic RetinoblastomaClinical Features, Treatment, and Prognosis
Gündüz, K., Müftüoğlu, O., Günalp, İ., Ünal, E., & Taçyıldız, N. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.03.039 · Cited by 119
Cascalló, M., Alonso, M. M., Rojas, J. J., Pérez, A., Fueyo-Margareto, J., & Alemany, R. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300239 · Cited by 117 · cited 11×
“RB1−/− cells lacked expression of RB1 protein and showed twofold higher E2F-1 expression than RB1+/− cells (fig.”
BackgroundInfluentialSelf-citationDifferential gene expression profile of retinoblastoma compared to normal retina.
Ganguly, A. A., & Shields, C. L. (2010) · PubMed Central · Cited by 112
Mizuguchi, H., Koizumi, N., Hosono, T., Ishii‐Watabe, A., Uchida, E., Utoguchi, N., Watanabe, Y., & Hayakawa, T. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301701 · Cited by 106
Compensation by tumor suppressor genes during retinal development in mice and humans
Donovan, S. L., Schweers, B., Martins, R., Johnson, D., & Dyer, M. A. (2006) · BMC Biology · doi:10.1186/1741-7007-4-14 · Cited by 105 · cited 1×
“In the first case, low expression of the E2F1 gene found in the developing retinas was consistent with sustained expression of RB1 in the normal mouse and human fetal retinas during development (42).”
BackgroundReeh, M., Bockhorn, M., Görgens, D., Vieth, M. W., Hoffmann, T. K., Simon, R., Izbicki, J. R., Sauter, G., Schumacher, U., & Anders, M. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.509 · Cited by 82 · cited 2×
“Cell receptors involved in adenovirus entry to host cells include the coxsackie adenovirus receptor (CAR; CXADR gene), a glycoprotein expressed in tumors including retinoblastoma cell lines Y79 and WERI-Rb1 (24, 25), and v3 and v5 integrins, which are receptors expressed by several cancer types (26).”
BackgroundUnderstanding pRb: toward the necessary development of targeted treatments for retinoblastoma
Sachdeva, U. M., & O’Brien, J. M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci57114 · Cited by 67 · cited 1×
“In retinoblastoma, the inactivation of RB1 removes the constraint on cell cycle control and constitutively increases the expression of free E2F (19).”
BackgroundSangwan, M., McCurdy, S. R., Livne-bar, I., Ahmad, M., Wrana, J. L., Chen, D., & Bremner, R. (2012) · Oncogene · doi:10.1038/onc.2011.654 · Cited by 66 · cited 1×
“Heterozygous deletion of the E2F1 gene prevents retinoblastoma activation in murine models (20).”
BackgroundComparative Ocular Anatomy in Commonly Used Laboratory Animals
Vézina, M. (2012) · Molecular and integrative toxicology · doi:10.1007/978-1-62703-164-6_1 · Cited by 64
Treatment of Invasive Retinoblastoma in a Murine Model Using an Oncolytic Picornavirus
Wadhwa, L., Hurwitz, M. Y., Chévez‐Barrios, P., & Hurwitz, R. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2352 · Cited by 58 · cited 1×
“A preclinical study in mice showed that an oncolytic Seneca Valley virus inhibited metastasis of the Y79 cell line to the brain compared with no treatment (50), although in this study the administration route was intravenous.”
BackgroundThe Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma
Martínez-Vélez, N., Xipell, E., Vera, B., de la Rocha, A. A., Zalacaín, M., Marrodán, L., González-Huarriz, M., Toledo, G., Cascalló, M., Alemany, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1899 · Cited by 57 · cited 1×
“Through these mechanisms, VCN-01 selectively infects and replicates in cancer cells, leading to antitumor activity in a variety of cancer models (21, 28).”
BackgroundSelf-citationBayó-Puxan, N., Giménez-Alejandre, M., Lavilla-Alonso, S., Gros, A., Cascalló, M., Hemminki, A., & Alemany, R. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.038 · Cited by 52 · cited 2×
“The human adenovirus VCN-01 and the nonreplicative AdTLRGDK vector were previously developed and characterized in detail (21, 32).”
MethodResultSelf-citationCook, J. L., Walker, T. A., Lewis, A. M., Ruley, H. E., Graham, F. L., & Pilder, S. H. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.18.6965 · Cited by 50
Mallam, J. N., Hurwitz, M. Y., Mahoney, T., Che´vez-Barrios, P., & Hurwitz, R. L. (2004) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.03-0730 · Cited by 43 · cited 2×
“Cell receptors involved in adenovirus entry to host cells include the coxsackie adenovirus receptor (CAR; CXADR gene), a glycoprotein expressed in tumors including retinoblastoma cell lines Y79 and WERI-Rb1 (24, 25), and v3 and v5 integrins, which are receptors expressed by several cancer types (26).”
BackgroundManagement of Retinoblastoma in Children: Current Status
Chantada, G. L., & Schaiquevich, P. S. (2015) · Pediatric Drugs · doi:10.1007/s40272-015-0121-9 · Cited by 37
Self-citationEye Size in Retinoblastoma: MR Imaging Measurements in Normal and Affected Eyes
de Graaf, P., Knol, D. L., Moll, A. C., Imhof, S. M., Meeteren, A. Y. N. S., & Castelijns, J. A. (2007) · Radiology · doi:10.1148/radiol.2441060456 · Cited by 37
Pascual‐Pasto, G., Olaciregui, N. G., Vilà-Ubach, M., Paco, S., Monterrubio, C., Rodríguez, E., Winter, U., Batalla-Vilacis, M., Català, J., Salvador, H., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.06.012 · Cited by 37
Self-citationSeggern, D. J. V., Aguilar, E., Kinder, K., Fleck, S. K., Armas, J. C. G., Stevenson, S. C., Ghazal, P., Nemerow, G. R., & Friedlander, M. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(02)00030-8 · Cited by 33
Intra‐arterial chemotherapy for retinoblastoma. Challenges of a prospective study
Parareda, A., Català, J., Carcaboso, A. M., Solá, T., Cruz, O., Díaz‐Cascajosa, J., Salvador, H., de Torres, C., Álvarez‐Sampons, A., Suñol, M., et al. (2013) · Acta Ophthalmologica · doi:10.1111/aos.12295 · Cited by 31 · cited 1×
“Otherwise, intensive local chemotherapy might preserve eyes; however, there may be an associated cost of compromised vision due to long-term retinal toxicity (5, 6).”
BackgroundSelf-citationKinnunen, K., Kalesnykas, G., Mähönen, A. J., Laidinen, S., Holma, L., Heikura, T., Airenne, K. J., Uusitalo, H. M. T., & Ylä‐Herttuala, S. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1311 · Cited by 27
Designing Adenoviral Vectors for Tumor-Specific Targeting
Alemany, R. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-561-9_2 · Cited by 25 · cited 1×
“Biodistribution of intravitreous VCN-01 is confined in the injected eye even in the presence of intraocular tumors Tumor-specific distribution is a desirable safety property of oncolytic adenoviruses (33).”
BackgroundSelf-citationIldefonso, C. J., Kong, L., Leen, A. M., Chai, S. J., Petrochelli, V., Chintagumpala, M., Hurwitz, M. Y., Chévez‐Barrios, P., & Hurwitz, R. L. (2010) · Molecular Therapy · doi:10.1038/mt.2010.139 · Cited by 24 · cited 1×
“Our finding of patient seroconversion is in contrast to a previous study showing the absence of systemic immune response after intravitreous administration of a nonreplicative Ad5 vector in retinoblastoma patients, although sampling times were not identical in both studies (51).”
ResultPavlidou, E., Burris, C. K. H., Thaung, C., Scheimberg, I. B., Kingston, J. E., Hungerford, J. L., Reddy, M. A., & Sagoo, M. S. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2015.2861 · Cited by 21 · cited 1×
“However, even after receiving maximum feasible dosages of drugs locally, some tumors progress to a chemoresistant phenotype (3).”
BackgroundIncreased delivery of chemotherapy to the vitreous by inhibition of the blood-retinal barrier
Pascual‐Pasto, G., Olaciregui, N. G., Opezzo, J. A. W., Castillo‐Ecija, H., Cuadrado‐Vilanova, M., Paco, S., Rivero, E. M., Vilà-Ubach, M., Restrepo‐Perdomo, C. A., Torrebadell, M., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.018 · Cited by 21 · cited 4×
“In addition, we have previously shown that this barrier remains intact in retinoblastoma (34).”
BackgroundMethodInfluentialSelf-citationUeyama, K., Mori, K., Shoji, T., Omata, H., Gehlbach, P. L., Brough, D. E., Wei, L. L., & Yoneya, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108071 · Cited by 20 · cited 1×
“VCN-01 did not replicate in the developing retinas of juvenile rabbits, and previous work has shown that Ad5 vectors either do not infect or induce short-term infections in the retina of mice (43, 44) and infect only the nerve fiber and ganglion cell layers, but not photoreceptors, in rabbits (45).”
BackgroundAlterations of cell cycle regulators affecting the RB pathway in nonfamilial retinoblastoma
Orjuela, M. A., Orlow, I., Dudas, M. E., Ponce-Castañeda, M. V., Ridaura, C., Leal, C., Salazar, A., Abramson, D. H., Gerald, W. L., & Cordon‐Cardo, C. (2001) · Human Pathology · doi:10.1053/hupa.2001.24325 · Cited by 16
Cited by
Exploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
Cancer vaccines: the next immunotherapy frontier
Lin, M. J., Svensson-Arvelund, J., Lubitz, G. S., Marabelle, A., Melero, I., Brown, B. D., & Brody, J. D. (2022) · Nature Cancer · doi:10.1038/s43018-022-00418-6 · Cited by 843
Recent advances of oncolytic virus in cancer therapy
Mondal, M., Guo, J., He, P., & Zhou, D. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1723363 · Cited by 224
“Recently a team of researchers from SJD Barcelona children’s hospital treated pediatric chemo-resistant retinoblastoma patients with intravitreous injection of VCN-01, and the results indicated enough viral replication in tumor cells to induce anti-tumor activity in retinoblastoma vitreous seeds and no systemic inflam…”
BackgroundMunier, F. L., Beck-Popovic, M., Chantada, G. L., Cobrinik, D., Kivelä, T. T., Lohmann, D., Maeder, P., Moll, A. C., Carcaboso, A. M., Moulin, A., et al. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.05.005 · Cited by 215
Self-citationDelivery and Biosafety of Oncolytic Virotherapy
Li, L., Liu, S., Han, D., Tang, B., & Ma, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00475 · Cited by 159
“Direct intratumoral injection of oncolytic adenovirus VCN-01 for the treatment of retinoblastoma has also been shown to be effective (46).”
Background
Metadata
- Authors
- Pascual-Pasto, G., Bazan-Peregrino, M., Olaciregui, N. G., Restrepo-Perdomo, C. A., Mato-Berciano, A., Ottaviani, D., Weber, K., Correa, G., Paco, S., Vila-Ubach, M., Cuadrado-Vilanova, M., Castillo-Ecija, H., Botteri, G., Garcia-Gerique, L., Moreno-Gilabert, H., Gimenez-Alejandre, M., Alonso-Lopez, P., Farrera-Sal, M., Torres-Manjon, S., Ramos-Lozano, D., Moreno, R., Aerts, I., Doz, F., Cassoux, N., Chapeaublanc, E., Torrebadell, M., Roldan, M., König, A., Suñol, M., Claverol, J., Lavarino, C., Carmen de, T., Fu, L., Radvanyi, F., Munier, F. L., Catalá-Mora, J., Mora, J., Alemany, R., Cascalló, M., Chantada, G. L., & Carcaboso, A. M.
- Affiliations
- Institut de Recerca Sant Joan de Deu, Barcelona 08950, Spain.
- VCN Biosciences, Sant Cugat del Valles, Barcelona 08174, Spain.
- Hospital Sant Joan de Déu Barcelona (ES)
- Pathology, Hospital Sant Joan de Deu, Barcelona 08950, Spain.
- Centre National de la Recherche Scientifique (FR)
- Chronobiotron (FR)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- Vivotecnia Research S.L., Tres Cantos, Madrid 28760, Spain.
- Pediatric Hematology-Oncology, Hospital Escuela Universitario, Tegucigalpa, Honduras.
- Hôpital Ophtalmique Jules-Gonin (CH)
- Ophthalmology, Hospital Sant Joan de Deu, Barcelona 08950, Spain.
- Corresponding author
- Carcaboso, Angel M.
- ORCID
- Pascual-Pasto, Guillem
- Bazan-Peregrino, Miriam
- Mato-Berciano, Ana
- Ottaviani, Daniela
- Weber, Klaus
- Paco, Sonia
- Castillo-Ecija, Helena
- Botteri, Gaia
- Garcia-Gerique, Laura
- Moreno-Gilabert, Helena
- Farrera-Sal, Marti
- Torres-Manjon, Silvia
- Moreno, Rafael
- Aerts, Isabelle
- Doz, François
- Cassoux, Nathalie
- Chapeaublanc, Elodie
- Torrebadell, Montserrat
- Suñol, Mariona
- Claverol, Joana
- Lavarino, Cinzia
- Radvanyi, François
- Munier, Francis L.
- Catalá-Mora, Jaume
- Alemany, Ramón
- Cascalló, Manel
- Chantada, Guillermo L.
- Carcaboso, Angel M.
- Venue
- Science Translational Medicine
- Published
- 2019-01-23
- Volume
- 11
- Issue
- 476
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2911889173
- Cited by
- 118
- References
- 57
- Citations by year
- 2026: 8 · 2025: 19 · 2024: 23 · 2023: 15 · 2022: 17 · 2021: 15 · 2020: 14 · 2019: 7
- FWCI
- 7.99
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by-nc-sa
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- IRIS (submittedVersion)
- Conicet (submittedVersion, cc-by-nc-sa)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- Seventh Framework Programme (PIRG-08-GA-2010-276998)
- Institut national de la santé et de la recherche médicale (Cancer plan)
- Fundación Científica Asociación Española Contra el Cáncer (Ayuda Retorno Investigadores)
- Instituto de Salud Carlos III (CP13/00189)
- Institut National Du Cancer
- Ministerio de Economía, Industria y Competitividad, Gobierno de España (Cure4RB project RTC-2015-4319-1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Keywords
- retinoblastoma, oncolytic adenovirus, E2F1, brain metastasis prevention, chemoresistance, vitreous inflammation, ocular survival
- MeSH terms
- Adenoviridae, Animals, Cytotoxicity, Immunologic, Humans, Neoplasm Metastasis, Rabbits, Retinoblastoma, Tissue Distribution, Virus Replication, Signal Transduction, Survival Analysis, Retinoblastoma Protein, Treatment Outcome, Xenograft Model Antitumor Assays, Cell Line, Tumor, Oncolytic Viruses, Mice, Translational Research, Biomedical, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.